Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Japan Industry Frets Fate of Astellas Worker Held in China for Espionage Allegation
Officials in the Japanese pharma industry are wringing their hands over the fate of a man detained in China earlier this month, who has been confirmed by Astellas Pharma to be one of its employees. Chinese authorities revealed on March…
To read the full story
Related Article
- Astellas Employee Did Not Appeal, Prison Sentence Finalized in China
July 29, 2025
- Astellas Employee Won’t Appeal China Espionage Sentence
July 22, 2025
- Astellas Employee Sentenced to 3.5 Years in China for Spying
July 17, 2025
- Verdict Due July 16 for Astellas Employee Detained in China
July 14, 2025
- Japan Will Persistently Urge China to Release Detained Astellas Employee: Govt
April 12, 2024
- 1 Year on, China Mulling Potential Indictment of Detained Astellas Employee
March 22, 2024
- Japan Ambassador Meets Astellas Employee Detained in China
November 29, 2023
- China Formally Arrests Astellas Employee, Japan Urges Immediate Release
October 20, 2023
- China to Soon Decide Whether to Arrest Detained Japanese Astellas Employee
September 21, 2023
- Japan Embassy Granted First In-Person Visit to Detained Astellas Employee
July 24, 2023
BUSINESS
- Teijin to Divest Feburic, Bonalon, Other Legacy Brands to LTL
June 18, 2026
- Acumen Exercises Option for Up to Two JCR-Enabled AD Candidates
June 18, 2026
- Takeda CEO Pulls in 2.3 Billion Yen in FY2025
June 18, 2026
- Elevidys Needs More Safety Data to Support Full Approval: Expert
June 18, 2026
- Sawai’s Revlimid Generic Gains Additional Lymphoma Indications
June 18, 2026
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…